1. Scrip
  2. >>Focus On Asia

China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public

 
• By Dexter Jie Yan

China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.

go public
Going public has become even more challenging for Chinese biotechs in a depressed stock market • Source: Shutterstock

China’s top securities regulator has confirmed a recent slowdown in the review of initial public offering applications to help stabilize the domestic stock market, making the go-public process for Chinese biotechs more unpredictable.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia